Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Phase 2 Completed 42 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well bortezomib works in treating patients with stage IIIB or stage IV lung cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2005-06
Primary completion: 2010-12
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	—	Intravenous

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Summary

Timeline

Drugs

Indications